{"id":"https://openalex.org/W2133310207","doi":"https://doi.org/10.1001/jama.2013.277165","title":"Anticoagulation With Otamixaban and Ischemic Events in Non\u2013ST-Segment Elevation Acute Coronary Syndromes","display_name":"Anticoagulation With Otamixaban and Ischemic Events in Non\u2013ST-Segment Elevation Acute Coronary Syndromes","publication_year":2013,"publication_date":"2013-09-01","ids":{"openalex":"https://openalex.org/W2133310207","doi":"https://doi.org/10.1001/jama.2013.277165","mag":"2133310207","pmid":"https://pubmed.ncbi.nlm.nih.gov/23995608"},"language":"en","primary_location":{"id":"doi:10.1001/jama.2013.277165","doi":"https://doi.org/10.1001/jama.2013.277165","is_oa":false,"landing_page_url":"https://doi.org/10.1001/jama.2013.277165","pdf_url":null,"source":{"id":"https://openalex.org/S172573765","display_name":"JAMA","issn_l":"0002-9955","issn":["0002-9955","0098-7484","1538-3598","2376-8118"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","datacite","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"http://jama.jamanetwork.com/article.aspx?articleid=1734212","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5003831287","display_name":"Philippe Gabr\u00edel Steg","orcid":"https://orcid.org/0000-0001-6896-2941","observed_orcids":["https://orcid.org/0000-0001-6896-2941"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I4210091437","display_name":"Sorbonne Paris Cit\u00e9","ror":"https://ror.org/001z21q04","country_code":"FR","type":"other","lineage":["https://openalex.org/I204730241","https://openalex.org/I4210091437"]},{"id":"https://openalex.org/I4210097159","display_name":"Assistance Publique \u2013 H\u00f4pitaux de Paris","ror":"https://ror.org/00pg5jh14","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159"]},{"id":"https://openalex.org/I4210145170","display_name":"H\u00f4pital Bichat-Claude-Bernard","ror":"https://ror.org/03fdnmv92","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210097159","https://openalex.org/I4210145170"]},{"id":"https://openalex.org/I4387154366","display_name":"Universit\u00e9 Paris Diderot","ror":"https://ror.org/02n7qrg46","country_code":"FR","type":"education","lineage":["https://openalex.org/I204730241","https://openalex.org/I4387154366"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"Philippe Gabriel Steg","raw_affiliation_strings":["Universit\u00e9 Paris-Diderot, Sorbonne-Paris Cit\u00e9, Paris, France. gabriel.steg@bch.aphp.fr","Universit\u00e9 Paris-Diderot, Sorbonne-Paris Cit\u00e9, Paris, France, INSERM U-698, Paris, France, D\u00e9partement Hospitalo-Universitaire FIRE, H\u00f4pital Bichat, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Universit\u00e9 Paris-Diderot, Sorbonne-Paris Cit\u00e9, Paris, France. gabriel.steg@bch.aphp.fr","institution_ids":["https://openalex.org/I4210091437","https://openalex.org/I4387154366"]},{"raw_affiliation_string":"Universit\u00e9 Paris-Diderot, Sorbonne-Paris Cit\u00e9, Paris, France, INSERM U-698, Paris, France, D\u00e9partement Hospitalo-Universitaire FIRE, H\u00f4pital Bichat, Assistance Publique\u2013H\u00f4pitaux de Paris, Paris, France","institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210091437","https://openalex.org/I4210097159","https://openalex.org/I4210145170","https://openalex.org/I4387154366"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":5,"corresponding_author_ids":["https://openalex.org/A5003831287"],"corresponding_institution_ids":["https://openalex.org/I154526488","https://openalex.org/I4210091437","https://openalex.org/I4210097159","https://openalex.org/I4210145170","https://openalex.org/I4387154366"],"apc_list":null,"apc_paid":null,"fwci":6.5445,"has_fulltext":false,"cited_by_count":73,"citation_normalized_percentile":{"value":0.97535134,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"310","issue":"11","first_page":"1145","last_page":"1145"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11064","display_name":"Antiplatelet Therapy and Cardiovascular Diseases","score":0.47850000858306885,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11064","display_name":"Antiplatelet Therapy and Cardiovascular Diseases","score":0.47850000858306885,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10292","display_name":"Acute Myocardial Infarction Research","score":0.413100004196167,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10881","display_name":"Blood Coagulation and Thrombosis Mechanisms","score":0.061500001698732376,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/otamixaban","display_name":"otamixaban","score":0.9639999866485596},{"id":"https://openalex.org/keywords/non-st-elevation-acute-coronary-syndrome","display_name":"non-ST-elevation acute coronary syndrome","score":0.8960000276565552},{"id":"https://openalex.org/keywords/direct-factor-xa-inhibitors","display_name":"direct factor Xa inhibitors","score":0.8159999847412109},{"id":"https://openalex.org/keywords/unfractionated-heparin","display_name":"unfractionated heparin","score":0.9390000104904175},{"id":"https://openalex.org/keywords/eptifibatide","display_name":"eptifibatide","score":0.9980000257492065},{"id":"https://openalex.org/keywords/early-invasive-strategy","display_name":"early invasive strategy","score":0.8289999961853027},{"id":"https://openalex.org/keywords/percutaneous-coronary-intervention","display_name":"percutaneous coronary intervention","score":0.9789999723434448},{"id":"https://openalex.org/keywords/bleeding-complications","display_name":"bleeding complications","score":0.6349999904632568},{"id":"https://openalex.org/keywords/ischemic-events","display_name":"ischemic events","score":0.7850000262260437},{"id":"https://openalex.org/keywords/all-cause-mortality","display_name":"all-cause mortality","score":0.7049999833106995},{"id":"https://openalex.org/keywords/myocardial-infarction","display_name":"myocardial infarction","score":0.9330000281333923},{"id":"https://openalex.org/keywords/anticoagulation","display_name":"anticoagulation","score":0.7260000109672546},{"id":"https://openalex.org/keywords/thrombosis","display_name":"thrombosis","score":0.3700000047683716},{"id":"https://openalex.org/keywords/drug-safety-and-efficacy-comparison","display_name":"drug safety and efficacy comparison","score":0.5580000281333923},{"id":"https://openalex.org/keywords/dose-selection","display_name":"dose selection","score":0.46700000762939453}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9739448428153992},{"id":"https://openalex.org/C2781056559","wikidata":"https://www.wikidata.org/wiki/Q2295855","display_name":"Eptifibatide","level":4,"score":0.897323727607727},{"id":"https://openalex.org/C2780400711","wikidata":"https://www.wikidata.org/wiki/Q2008344","display_name":"Percutaneous coronary intervention","level":3,"score":0.6393347978591919},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.6379433870315552},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.5480520725250244},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5443910360336304},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5213033556938171},{"id":"https://openalex.org/C2777698277","wikidata":"https://www.wikidata.org/wiki/Q266018","display_name":"Acute coronary syndrome","level":3,"score":0.4804805815219879},{"id":"https://openalex.org/C2777557582","wikidata":"https://www.wikidata.org/wiki/Q190016","display_name":"Heparin","level":2,"score":0.4449043869972229},{"id":"https://openalex.org/C43376680","wikidata":"https://www.wikidata.org/wiki/Q6580786","display_name":"Bolus (digestion)","level":2,"score":0.43067502975463867},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.4172661602497101},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3766419291496277}],"mesh":[{"descriptor_ui":"D000077542","descriptor_name":"Eptifibatide","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002423","descriptor_name":"Cause of Death","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003497","descriptor_name":"Cyclic N-Oxides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003497","descriptor_name":"Cyclic N-Oxides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006470","descriptor_name":"Hemorrhage","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D006493","descriptor_name":"Heparin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007275","descriptor_name":"Injections, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009203","descriptor_name":"Myocardial Infarction","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D009203","descriptor_name":"Myocardial Infarction","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":false},{"descriptor_ui":"D010455","descriptor_name":"Peptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012306","descriptor_name":"Risk","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019039","descriptor_name":"Platelet Glycoprotein GPIIb-IIIa Complex","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D054058","descriptor_name":"Acute Coronary Syndrome","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D054058","descriptor_name":"Acute Coronary Syndrome","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D062645","descriptor_name":"Percutaneous Coronary Intervention","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065427","descriptor_name":"Factor Xa Inhibitors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":6,"locations":[{"id":"doi:10.1001/jama.2013.277165","doi":"https://doi.org/10.1001/jama.2013.277165","is_oa":false,"landing_page_url":"https://doi.org/10.1001/jama.2013.277165","pdf_url":null,"source":{"id":"https://openalex.org/S172573765","display_name":"JAMA","issn_l":"0002-9955","issn":["0002-9955","0098-7484","1538-3598","2376-8118"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA","raw_type":"journal-article"},{"id":"pmid:23995608","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23995608","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA","raw_type":"Journal Article"},{"id":"pmh:002416509","doi":null,"is_oa":true,"landing_page_url":"http://jama.jamanetwork.com/article.aspx?articleid=1734212","pdf_url":null,"source":{"id":"https://openalex.org/S4306402641","display_name":"LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Cient\u00edficas)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4383465926","host_organization_name":"LA Referencia","host_organization_lineage":["https://openalex.org/I4383465926"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"reponame:Reposit\u00f3rio Institucional da USP","raw_type":"info:eu-repo/semantics/publishedVersion"},{"id":"pmh:oai:www.zora.uzh.ch:90038","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/id/eprint/90038/1/joi130054.pdf","pdf_url":"https://www.zora.uzh.ch/id/eprint/90038/1/joi130054.pdf","source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Steg, Philippe Gabriel; Mehta, Shamir R; Pollack, Charles V; et al (2013). Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA : the Journal of the American Medical Association, 310(11):1145-1155.","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:www.zora.uzh.ch:20.500.14742/100309","doi":null,"is_oa":true,"landing_page_url":"https://www.zora.uzh.ch/handle/20.500.14742/100309","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Steg, P. G., Mehta, S. R., Pollack, C. V., & et al. (2013). Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA\u202f: The Journal of the American Medical Association, 310, 1145\u20131155. https://doi.org/10.1001/jama.2013.277165","raw_type":"Journal Article"},{"id":"doi:10.5167/uzh-90038","doi":"https://doi.org/10.5167/uzh-90038","is_oa":true,"landing_page_url":"https://doi.org/10.5167/uzh-90038","pdf_url":null,"source":{"id":"https://openalex.org/S4306401281","display_name":"Zurich Open Repository and Archive (University of Zurich)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I202697423","host_organization_name":"University of Zurich","host_organization_lineage":["https://openalex.org/I202697423"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"JournalArticle"}],"best_oa_location":{"id":"pmh:002416509","doi":null,"is_oa":true,"landing_page_url":"http://jama.jamanetwork.com/article.aspx?articleid=1734212","pdf_url":null,"source":{"id":"https://openalex.org/S4306402641","display_name":"LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Cient\u00edficas)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4383465926","host_organization_name":"LA Referencia","host_organization_lineage":["https://openalex.org/I4383465926"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"reponame:Reposit\u00f3rio Institucional da USP","raw_type":"info:eu-repo/semantics/publishedVersion"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":29,"referenced_works":["https://openalex.org/W153597901","https://openalex.org/W206747855","https://openalex.org/W246948802","https://openalex.org/W1547524180","https://openalex.org/W1977392148","https://openalex.org/W1980315530","https://openalex.org/W2004025677","https://openalex.org/W2025513998","https://openalex.org/W2031395291","https://openalex.org/W2053420707","https://openalex.org/W2054569765","https://openalex.org/W2073159589","https://openalex.org/W2081592636","https://openalex.org/W2082830466","https://openalex.org/W2087150869","https://openalex.org/W2093279552","https://openalex.org/W2096002945","https://openalex.org/W2098332177","https://openalex.org/W2105397247","https://openalex.org/W2120569650","https://openalex.org/W2122779695","https://openalex.org/W2126830306","https://openalex.org/W2132393613","https://openalex.org/W2133326664","https://openalex.org/W2134124835","https://openalex.org/W2138733869","https://openalex.org/W2147270034","https://openalex.org/W2170949977","https://openalex.org/W3170020307"],"related_works":["https://openalex.org/W2133326664","https://openalex.org/W2081592636","https://openalex.org/W2144508450","https://openalex.org/W2083726232","https://openalex.org/W2057285779","https://openalex.org/W2007515753","https://openalex.org/W2332658614","https://openalex.org/W4205867172","https://openalex.org/W6892248708","https://openalex.org/W2151909965"],"abstract_inverted_index":{"IMPORTANCE:":[0],"The":[1,128,155,225],"optimal":[2],"anticoagulant":[3],"for":[4,97,216,294],"patients":[5,46,67,295],"with":[6,14,37,47,68,296],"non-ST-segment":[7],"elevation":[8],"acute":[9],"coronary":[10,125,302],"syndromes":[11],"(NSTE-ACS)":[12],"managed":[13],"an":[15,136,144],"invasive":[16,53,74],"strategy":[17],"remains":[18],"controversial.":[19],"OBJECTIVE:":[20],"To":[21],"compare":[22],"the":[23,121,160,175,217,270,290],"clinical":[24],"efficacy":[25,157,177],"and":[26,70,83,88,109,189],"safety":[27,227],"of":[28,39,113,123,139,146,162,174,182,192,229,272,292],"otamixaban,":[29],"a":[30,50,71],"novel":[31],"intravenous":[32,137],"direct":[33],"factor":[34],"Xa":[35],"inhibitor,":[36],"that":[38,64],"unfractionated":[40,117,198,277],"heparin":[41,118,199,278],"plus":[42,200,279],"downstream":[43],"eptifibatide":[44,201,280],"in":[45,80,231],"NSTE-ACS":[48,69,297],"undergoing":[49,298],"planned":[51,72,92,299],"early":[52,73,300],"strategy.":[54],"DESIGN,":[55],"SETTING,":[56],"AND":[57,153,264],"PARTICIPANTS:":[58],"Randomized,":[59],"double-blind,":[60],"active-controlled":[61],"superiority":[62],"trial":[63],"enrolled":[65],"13,229":[66],"strategy,":[75],"at":[76,111,120,132],"568":[77],"active":[78],"sites":[79],"55":[81],"countries":[82],"conducted":[84,96],"between":[85],"April":[86],"2010":[87],"February":[89],"2013.":[90],"A":[91],"interim":[93,133],"analysis":[94,134],"was":[95,135,159,241],"otamixaban":[98,107,129,188,244,293],"dose":[99,130],"selection.":[100],"INTERVENTIONS:":[101],"Eligible":[102],"participants":[103],"were":[104,179,213,258],"randomized":[105,185,195],"to":[106,186,196,276],"(bolus":[108],"infusion,":[110],"1":[112],"2":[114],"doses)":[115],"or":[116,165,235],"plus,":[119],"time":[122],"percutaneous":[124,301],"intervention,":[126],"eptifibatide.":[127],"selected":[131],"bolus":[138],"0.080":[140],"mg/kg":[141,148],"followed":[142],"by":[143,243],"infusion":[145],"0.140":[147],"per":[149],"hour.":[150],"MAIN":[151],"OUTCOMES":[152],"MEASURES:":[154],"primary":[156,176,226],"outcome":[158,178,228],"composite":[161],"all-cause":[163],"death":[164],"new":[166],"myocardial":[167],"infarction":[168],"through":[169,238],"day":[170,239],"7.":[171],"RESULTS:":[172],"Rates":[173],"5.5%":[180],"(279":[181],"5105":[183],"patients)":[184,194],"receive":[187,197],"5.7%":[190],"(310":[191],"5466":[193],"(adjusted":[202],"relative":[203,248,275],"risk,":[204,249],"0.99":[205],"[95%":[206,251],"CI,":[207,252],"0.85-1.16];":[208],"P":[209,254],"=":[210],".93).":[211],"There":[212],"no":[214],"differences":[215],"secondary":[218],"end":[219],"points,":[220],"including":[221],"procedural":[222],"thrombotic":[223],"complications.":[224],"Thrombosis":[230],"Myocardial":[232],"Infarction":[233],"major":[234],"minor":[236],"bleeding":[237],"7":[240],"increased":[242],"(3.1%":[245],"vs":[246],"1.5%;":[247],"2.13":[250],"1.63-2.78];":[253],"<":[255],".001).":[256],"Results":[257],"consistent":[259],"across":[260],"prespecified":[261],"subgroups.":[262],"CONCLUSIONS":[263],"RELEVANCE:":[265],"Otamixaban":[266],"did":[267,282],"not":[268,288],"reduce":[269],"rate":[271],"ischemic":[273],"events":[274],"but":[281],"increase":[283],"bleeding.":[284],"These":[285],"findings":[286],"do":[287],"support":[289],"use":[291],"intervention.":[303],"TRIAL":[304],"REGISTRATION:":[305],"clinicaltrials.gov":[306],"Identifier:":[307],"NCT01076764.":[308]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":14},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":15},{"year":2013,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}